However, the failure of interferon-gamma, a potent immune activator, to benefit GBM patients and the association of a fraction of gene markers that efficiently characterize the immune-mediated tumor elimination with poor prognosis in GBM patients are highly suggestive of the uniqueness of the immunological property of GBM (Wolff et al., 2006; Qian et al., 2018; Wang et al., 2019). This evidence concerns the gene IFNG and neoplasm.